Table 7.
Pathological upgrading of prostate adenocarcinoma patients undergoing surgery with PSA levels below 4.0 ng/ml.
| Number of patients | Gleason score | Stage | Upgrade to csPCa | Upgrade of stage | ||
|---|---|---|---|---|---|---|
| Biopsy | Surgery | Biopsy | Surgery | |||
| 1 | 6 | 7 | T2aN0M0 | T2cN0M0 | Y | Y |
| 2 | 6 | 7 | T2aN0M0 | T2cN0M0 | Y | Y |
| 3 | 6 | 7 | T2aN0M0 | T2cN0M0 | Y | Y |
| 4 | 6 | 8 | T2aN0M0 | T2cN0M0 | Y | Y |
| 5 | 6 | 6 | T2aN0M0 | T2cN0M0 | N | Y |
| 6 | 6 | 6 | T2aN0M0 | T2cN0M0 | N | Y |
| 7 | 6 | 6 | T2aN0M0 | T2cN0M0 | N | Y |
| 8 | 7 | 7 | T2aN0M0 | T3aN0M0 | N | Y |
| 9 | 9 | 9 | T2bN0M0 | T2cN0M0 | N | Y |
| 10 | 6 | 6 | T2aN0M0 | T2aN0M0 | N | N |
| 11 | 6 | 6 | T2cN0M0 | T2cN0M0 | N | N |
| 12 | 6 | 6 | T2cN0M0 | T2cN0M0 | N | N |
| 13 | 7 | 7 | T3bN0M0 | T3bN0M0 | N | N |
| 14 | 7 | 7 | T2cN0M0 | T2cN0M0 | N | N |
csPCa, clinically significant prostate cancer; Y, yes; N, no.